JP2018529759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529759A5 JP2018529759A5 JP2018526974A JP2018526974A JP2018529759A5 JP 2018529759 A5 JP2018529759 A5 JP 2018529759A5 JP 2018526974 A JP2018526974 A JP 2018526974A JP 2018526974 A JP2018526974 A JP 2018526974A JP 2018529759 A5 JP2018529759 A5 JP 2018529759A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- rna molecule
- target region
- inhibitor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 20
- 102100039290 Gap junction gamma-1 protein Human genes 0.000 claims description 16
- 101710178004 Gap junction gamma-1 protein Proteins 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 206010003119 arrhythmia Diseases 0.000 claims description 12
- 230000006793 arrhythmia Effects 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 206010006578 Bundle-Branch Block Diseases 0.000 claims description 6
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 6
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 5
- 206010071186 Ventricular dyssynchrony Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010003671 Atrioventricular Block Diseases 0.000 claims description 3
- 206010006580 Bundle branch block left Diseases 0.000 claims description 3
- 206010006582 Bundle branch block right Diseases 0.000 claims description 3
- 238000007914 intraventricular administration Methods 0.000 claims description 3
- 201000001715 left bundle branch hemiblock Diseases 0.000 claims description 3
- 201000007916 right bundle branch block Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000306 qrs interval Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021104925A JP7668686B2 (ja) | 2015-08-14 | 2021-06-24 | 治療用コネキシン４５阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903282A AU2015903282A0 (en) | 2015-08-14 | Connexin 45 Inhibition for Therapy | |
| AU2015903282 | 2015-08-14 | ||
| PCT/AU2016/050740 WO2017027910A1 (en) | 2015-08-14 | 2016-08-12 | Connexin 45 inhibition for therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021104925A Division JP7668686B2 (ja) | 2015-08-14 | 2021-06-24 | 治療用コネキシン４５阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529759A JP2018529759A (ja) | 2018-10-11 |
| JP2018529759A5 true JP2018529759A5 (enExample) | 2020-12-24 |
Family
ID=58050389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526974A Pending JP2018529759A (ja) | 2015-08-14 | 2016-08-12 | 治療用コネキシン４５阻害剤 |
| JP2021104925A Active JP7668686B2 (ja) | 2015-08-14 | 2021-06-24 | 治療用コネキシン４５阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021104925A Active JP7668686B2 (ja) | 2015-08-14 | 2021-06-24 | 治療用コネキシン４５阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10709726B2 (enExample) |
| EP (2) | EP3334746B1 (enExample) |
| JP (2) | JP2018529759A (enExample) |
| AU (2) | AU2016309948B2 (enExample) |
| CA (1) | CA3033909A1 (enExample) |
| WO (1) | WO2017027910A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200061210A1 (en) * | 2018-08-27 | 2020-02-27 | BioViva USA, Inc. | Novel method for gene therapy using intranasal administration of genetically modified viral vectors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA962806A (en) | 1970-06-04 | 1975-02-18 | Ontario Research Foundation | Surgical prosthetic device |
| US4101984A (en) | 1975-05-09 | 1978-07-25 | Macgregor David C | Cardiovascular prosthetic devices and implants with porous systems |
| US4281669A (en) | 1975-05-09 | 1981-08-04 | Macgregor David C | Pacemaker electrode with porous system |
| IT1196836B (it) | 1986-12-12 | 1988-11-25 | Sorin Biomedica Spa | Protesi in materiale polimerico con rivestimento di carbonio biocompatibile |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5163958A (en) | 1989-02-02 | 1992-11-17 | Cordis Corporation | Carbon coated tubular endoprosthesis |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5236457A (en) | 1992-02-27 | 1993-08-17 | Zimmer, Inc. | Method of making an implant having a metallic porous surface |
| US6613749B1 (en) | 1994-07-26 | 2003-09-02 | Imperial College Innovations Limited | Papovavirus pseudocapsids and use thereof for exogenous material transfer |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP0862419B2 (en) | 1995-11-09 | 2010-11-17 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
| US20020001574A1 (en) | 1995-12-13 | 2002-01-03 | Jon A. Woiff | Process of delivering a polynucleotide to a muscle cell via the vascular system |
| US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE19855421C2 (de) | 1998-11-02 | 2001-09-20 | Alcove Surfaces Gmbh | Implantat |
| KR20030045847A (ko) | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | 코팅된 이식형 의료 장치 |
| AU2003256540B2 (en) | 2002-07-12 | 2008-12-11 | Cook Medical Technologies Llc | Coated medical device |
| KR100826574B1 (ko) | 2002-11-13 | 2008-04-30 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 다공성 층을 갖는 의료장치 및 이를 제조하는 방법 |
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| ES2749374T3 (es) * | 2003-12-03 | 2020-03-20 | Ocunexus Therapeutics Inc | Compuestos inhibitorios dirigidos a conexina 43 y sus métodos de uso en el tratamiento del trauma ocular de la córnea |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| WO2006134494A2 (en) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and therapeutic uses thereof |
| US20180099029A9 (en) | 2010-04-15 | 2018-04-12 | Mount Sinai School Of Medicine | Serca2 therapeutic compositions and methods of use |
| EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2655621B1 (en) * | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| KR20230065381A (ko) | 2012-07-25 | 2023-05-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용 |
| EP2880171B1 (en) | 2012-08-03 | 2018-10-03 | The Regents of The University of California | Methods and compositions for controlling gene expression by rna processing |
| CN110669758A (zh) | 2012-10-23 | 2020-01-10 | 基因工具股份有限公司 | 用于切割靶dna 的组合物及其用途 |
| CA3034794A1 (en) | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| EP4234696A3 (en) | 2012-12-12 | 2023-09-06 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| RU2721275C2 (ru) | 2012-12-12 | 2020-05-18 | Те Брод Инститьют, Инк. | Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CA2951721C (en) | 2014-06-12 | 2023-09-26 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
-
2016
- 2016-08-12 US US15/751,802 patent/US10709726B2/en active Active
- 2016-08-12 EP EP16836267.1A patent/EP3334746B1/en active Active
- 2016-08-12 WO PCT/AU2016/050740 patent/WO2017027910A1/en not_active Ceased
- 2016-08-12 CA CA3033909A patent/CA3033909A1/en active Pending
- 2016-08-12 EP EP21209350.4A patent/EP4043074A1/en not_active Withdrawn
- 2016-08-12 AU AU2016309948A patent/AU2016309948B2/en active Active
- 2016-08-12 JP JP2018526974A patent/JP2018529759A/ja active Pending
-
2021
- 2021-06-24 JP JP2021104925A patent/JP7668686B2/ja active Active
- 2021-08-13 AU AU2021215254A patent/AU2021215254A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hori et al. | Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients With Non-Valvular Atrial Fibrillation–Subanalysis of J-ROCKET AF for Patients With Moderate Renal Impairment– | |
| Soto‐Rifo et al. | The role of the DEAD‐box RNA helicase DDX3 in mRNA metabolism | |
| JP2017158561A5 (enExample) | ||
| CN111542343A (zh) | 抗bcma的单域抗体及其应用 | |
| JP2016538885A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2014094951A5 (enExample) | ||
| JP2017510552A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| JP2019508045A5 (enExample) | ||
| JP2015514778A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| JPWO2019107530A5 (enExample) | ||
| JP2020535845A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| JP2018501791A5 (enExample) | ||
| US20160271083A1 (en) | Treatment of cardiac remodeling and other heart conditions | |
| JP2017141225A5 (enExample) | ||
| JP2017533910A5 (enExample) | ||
| Urban et al. | Distinct functions of human RecQ helicases during DNA replication | |
| JP2013504603A5 (enExample) | ||
| Jarr et al. | TNF‐like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice | |
| BR112023016631A2 (pt) | Inibidores de apol1 e métodos de uso |